[PDF] Top 20 Co-activation of AMPK and mTORC1 Induce Cytotoxicity in Acute Myeloid Leukemia
Has 10000 "Co-activation of AMPK and mTORC1 Induce Cytotoxicity in Acute Myeloid Leukemia" found on our website. Below are the top 20 most common "Co-activation of AMPK and mTORC1 Induce Cytotoxicity in Acute Myeloid Leukemia".
Co-activation of AMPK and mTORC1 Induce Cytotoxicity in Acute Myeloid Leukemia
... SUMMARY AMPK is a master regulator of cellular metabolism that exerts either oncogenic or tumor suppressor activity depending on ...specific AMPK agonist GSK621 selectively kills acute ... Voir le document complet
14
Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia
... involved in other crucial metabolic pathways such as the pentose phosphate path- way (PPP) coupled to NADPH production, glutathione/ redox recycling, and nucleotide biosynthesis ...Overexpression of ... Voir le document complet
18
Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3‐ITD‐driven acute myeloid leukemia
... Introduction Acute myeloid leukaemia (AML) is a clonal disorder that affects hematopoietic stem cells or myeloid ...accumulation of immature leukemic cells in the bone marrow and ... Voir le document complet
24
Metabolic stress controls mutant p53 R248Q stability in acute myeloid leukemia cells
... tumors and potentially improve the prognosis of cancer patients. In this study, we unveil different mechanisms that eliminate p53-R248Q, one of the most frequent mutants found in human ... Voir le document complet
38
Dendrogenin A Enhances Anti-Leukemic Effect of Anthracycline in Acute Myeloid Leukemia
... 4 of 14 2.2. Idarubicin Combined with DDA Synergistically Induce AML Cell Death Using the same conditions as described above with daunorubicin, the pretreatment of KG1a cells with DDA did not affect ... Voir le document complet
15
ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.
... incidence of grade II –IV acute GVHD. These data are in agreement with those reported by Bacigalupu and colleagues 29 showing that patients with major ABO incompatibility experienced lower ... Voir le document complet
8
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients
... (MAC) and reduced-intensity conditioning (RIC) or nonmyeloablative (NMA) based on the expected duration of the pancyto- penia (irreversible, prolonged, minimal) and on the requirement for stem cell ... Voir le document complet
12
en fr Targeting NPM1c in Acute Myeloid leukemia NPM1C, une cible dans le traitement des leucémies aigues myéloides
... survival of chemotherapy-treated Nucleophosmin-1 mutated Acute Myeloid Leukemia patients (NPM1-mutant ...reactivation and growth arrest. The promyelocytic leukemia protein (PML) ... Voir le document complet
241
Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms
... used in eligible patients but the response rate is low, toxicity and mortality high with poor long term results 5 ...limited and confirmation is warranted 6 ... Voir le document complet
30
Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients
... trial in hospitalized patients with AML/ high-risk myelodysplastic syndrome to assess the feasibility and tolerance of AFMT in the setting of IC and antibiotic therapy given ... Voir le document complet
12
Understanding the transcriptional control of EIF4E and its dysregulation in acute myeloid leukemia: role of NF-κB
... control of EIF4E, our findings strongly suggest that NF-κB activity is likely heterogeneous amongst AML specimens with regard to other targeted ...promoters. In other words, the NF-κB dependent ... Voir le document complet
154
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia
... <0.05 and absolute fold change ...exploration and mining. Lists of DE mRNA (FC > ±1.5 and FDR < ...loaded in the Genome Analyzer bioinformatics tool (Genom‑ atix) for further ... Voir le document complet
16
Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia
... 3 of 17 2. Results and Discussion ...Dysregulated in IDH1 Mutant Cells We first compared the proteome of IDH1 mutant HL60 cells to the one of IDH1 WT ...list of proteins that are ... Voir le document complet
19
H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations
... hallmarks of decreased cellular proliferation or apoptosis. Through a series of CRISPR-Cas9 and RNAi experiments targeting UTX/JMJD3, it was demonstrated that sensitivity by GSK-J4 in RUNX1 ... Voir le document complet
89
Acute lymphoblastic leukemia in children
... Le nombre (n = 13 soit 16,5 %) d’échecs thé- rapeutiques (rechutes et patients réfractaires : plus de 25 % de blastes après l’induction) que nous avons observé est bas mais le taux de “r[r] ... Voir le document complet
7
Practical management of Chronic Myeloid Leukemia in Belgium
... consists of documenting the presence of the Philadelphia chromo- some by karyotype, fluorescent in situ hybridisation (FISH) or polymerase chain reaction (PCR) either on peripheral blood or on bone ... Voir le document complet
17
Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia
... nature of pPCL, our patient was frequently followed-up. The first signs of relapse occurred in Feb- ruary 2018; 6 months after high dose ...elevation of FLC lambda was accompanied by the ... Voir le document complet
4
Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON leukemia group trials
... " # $ % No markup for post-processing Safaa M. Ramadan, MD, PhD * , , Stefan Suciu, PhD , Marian J.P.L. Stevens-Kroef, PhD * , , Roelof Willemze, MD, PhD , Sergio Amadori , Theo de Witte, MD * , , Bob Lowenberg, MD, ... Voir le document complet
3
A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia
... details and conditions that other laboratories may use to quickly and routinely set up in vivo AML ...lines in the same experimental settings and mouse ...establishment of this ... Voir le document complet
8
STAT5-dependent regulation of CDC25A by miR-16 controls proliferation and differentiation in FLT3-ITD acute myeloid leukemia
... lysed in 60 μl of NuPAGE ® LDS Sample Buffer (Novex, Life Technologies, Carslbad, CA, USA), sonicated for 4 × 7 seconds, and boiled for 3 ...Gels and transferred to nitrocellulose ...hour ... Voir le document complet
13
Sujets connexes